Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation  Vienna Ludovini, PhD,

Published by Modified over 6 years ago

Similar presentations

Presentation on theme: "Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation  Vienna Ludovini, PhD,"— Presentation transcript:

1 Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation  Vienna Ludovini, PhD, Stefania Gori, MD, Lorenza Pistola, PhD  Journal of Thoracic Oncology  Volume 3, Issue 4, Pages (April 2008) DOI: /JTO.0b013e318169e341 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 (A) Computed tomography (CT) chest scan at relapse of disease (May 2005); (B) CT chest scan after gefitinib therapy (September 2006); (C) Sequencing of exon 20 shows two heterozygous mutations in tumor tissue DNA: a C to Y (C or T) base-pair change (red arrow), resulting in a substitution of phenylalanine for serine at position 784 (S784F); a G to R (A or G) base-pair change (black arrow), resulting in a substitution of methionine for valine at position 786 (V786M); (D) Sequencing of exon 20, derived from tumor tissue DNA, cloned fragment in plasmid: single mutation in homozygous shows a C to T base-pair change, resulting in a substitution of phenylalanine for serine at position 784 (S784F), (E) Single mutation in homozygous shows a G to A base-pair change, resulting in a substitution of methionine for valine at position 786 (V786M). Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e318169e341) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation  Vienna Ludovini, PhD,"

Similar presentations

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,
Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib  C. Leitner, R. von Moos,

Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib  C. Leitner, R. von Moos,
Inflammatory Myofibroblastic Tumor of the Left Main Stem Bronchus

Inflammatory Myofibroblastic Tumor of the Left Main Stem Bronchus
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients  Antonio Marchetti, MD, PhD,

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients  Antonio Marchetti, MD, PhD,
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
MET Mutation Associated with Responsiveness to Crizotinib

MET Mutation Associated with Responsiveness to Crizotinib
Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas  Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas  Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,
Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion  Eckart Laack, MD, Ronald.

Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion  Eckart Laack, MD, Ronald.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.

Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.
Simona Coco, PhD, Anna Truini, MS, Irene Vanni, MS, Carlo Genova, MD 

Simona Coco, PhD, Anna Truini, MS, Irene Vanni, MS, Carlo Genova, MD 
Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma  Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma  Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
Dramatic Response to Pemetrexed in a Patient with Pneumonic-Type Mucinous Bronchioloalveolar Carcinoma  David H. Garfield, MD, Wilbur Franklin, MD  Journal.

Dramatic Response to Pemetrexed in a Patient with Pneumonic-Type Mucinous Bronchioloalveolar Carcinoma  David H. Garfield, MD, Wilbur Franklin, MD  Journal.

Similar presentations

Ads by Google